Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.
To characterize WHO-defined transmitted HIV drug resistance mutation (TDRM) data from recently HIV-infected African volunteers, we sequenced HIV (pol) and evaluated for TDRM the earliest available specimens from ARV-naive volunteers diagnosed within 1 year of their estimated date of infection at eig...
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
2011
|
| _version_ | 1826277735725531136 |
|---|---|
| author | Price, M Wallis, C Lakhi, S Karita, E Kamali, A Anzala, O Sanders, E Bekker, L Twesigye, R Hunter, E Kaleebu, P Kayitenkore, K Allen, S Ruzagira, E Mwangome, M Mutua, G Amornkul, P Stevens, G Pond, S Schaefer, M Papathanasopoulos, M Stevens, W Gilmour, J |
| author_facet | Price, M Wallis, C Lakhi, S Karita, E Kamali, A Anzala, O Sanders, E Bekker, L Twesigye, R Hunter, E Kaleebu, P Kayitenkore, K Allen, S Ruzagira, E Mwangome, M Mutua, G Amornkul, P Stevens, G Pond, S Schaefer, M Papathanasopoulos, M Stevens, W Gilmour, J |
| author_sort | Price, M |
| collection | OXFORD |
| description | To characterize WHO-defined transmitted HIV drug resistance mutation (TDRM) data from recently HIV-infected African volunteers, we sequenced HIV (pol) and evaluated for TDRM the earliest available specimens from ARV-naive volunteers diagnosed within 1 year of their estimated date of infection at eight research centers in sub-Saharan Africa. TDRMs were detected in 19/408 (5%) volunteers. The prevalence of TDRMs varied by research center, from 5/26 (19%) in Entebbe, 6/78 (8%) in Kigali, 2/49 (4%) in Kilifi, to 3/106 (3%) in Lusaka. One of five volunteers from Cape Town (20%) had TDRMs. Despite small numbers, our data suggest an increase in DRMs by year of infection in Zambia (p = 0.004). The prevalence observed in Entebbe was high across the entire study. ARV history data from 12 (63%) HIV-infected sexual partners were available; 3 reported ARV use prior to transmission. Among four partners with sequence data available, transmission linkage was confirmed and two had the same TDRMs as the newly infected volunteer (both K103N). As ARV therapy continues to increase in availability throughout Africa, monitoring incident virus strains for the presence of TDRMs should be a priority. Early HIV infection cohorts provide an excellent and important platform to monitor the development of TDRMs to inform treatment guidelines, drug choices, and strategies for secondary prevention of TDRM transmission. |
| first_indexed | 2024-03-06T23:33:23Z |
| format | Journal article |
| id | oxford-uuid:6ccf86a5-ab29-43bf-abef-f860c476d581 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:33:23Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:6ccf86a5-ab29-43bf-abef-f860c476d5812022-03-26T19:13:38ZTransmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6ccf86a5-ab29-43bf-abef-f860c476d581EnglishSymplectic Elements at Oxford2011Price, MWallis, CLakhi, SKarita, EKamali, AAnzala, OSanders, EBekker, LTwesigye, RHunter, EKaleebu, PKayitenkore, KAllen, SRuzagira, EMwangome, MMutua, GAmornkul, PStevens, GPond, SSchaefer, MPapathanasopoulos, MStevens, WGilmour, JTo characterize WHO-defined transmitted HIV drug resistance mutation (TDRM) data from recently HIV-infected African volunteers, we sequenced HIV (pol) and evaluated for TDRM the earliest available specimens from ARV-naive volunteers diagnosed within 1 year of their estimated date of infection at eight research centers in sub-Saharan Africa. TDRMs were detected in 19/408 (5%) volunteers. The prevalence of TDRMs varied by research center, from 5/26 (19%) in Entebbe, 6/78 (8%) in Kigali, 2/49 (4%) in Kilifi, to 3/106 (3%) in Lusaka. One of five volunteers from Cape Town (20%) had TDRMs. Despite small numbers, our data suggest an increase in DRMs by year of infection in Zambia (p = 0.004). The prevalence observed in Entebbe was high across the entire study. ARV history data from 12 (63%) HIV-infected sexual partners were available; 3 reported ARV use prior to transmission. Among four partners with sequence data available, transmission linkage was confirmed and two had the same TDRMs as the newly infected volunteer (both K103N). As ARV therapy continues to increase in availability throughout Africa, monitoring incident virus strains for the presence of TDRMs should be a priority. Early HIV infection cohorts provide an excellent and important platform to monitor the development of TDRMs to inform treatment guidelines, drug choices, and strategies for secondary prevention of TDRM transmission. |
| spellingShingle | Price, M Wallis, C Lakhi, S Karita, E Kamali, A Anzala, O Sanders, E Bekker, L Twesigye, R Hunter, E Kaleebu, P Kayitenkore, K Allen, S Ruzagira, E Mwangome, M Mutua, G Amornkul, P Stevens, G Pond, S Schaefer, M Papathanasopoulos, M Stevens, W Gilmour, J Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title | Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title_full | Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title_fullStr | Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title_full_unstemmed | Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title_short | Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. |
| title_sort | transmitted hiv type 1 drug resistance among individuals with recent hiv infection in east and southern africa |
| work_keys_str_mv | AT pricem transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT wallisc transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT lakhis transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT karitae transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT kamalia transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT anzalao transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT sanderse transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT bekkerl transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT twesigyer transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT huntere transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT kaleebup transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT kayitenkorek transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT allens transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT ruzagirae transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT mwangomem transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT mutuag transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT amornkulp transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT stevensg transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT ponds transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT schaeferm transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT papathanasopoulosm transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT stevensw transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica AT gilmourj transmittedhivtype1drugresistanceamongindividualswithrecenthivinfectionineastandsouthernafrica |